Literature DB >> 29754212

Matrix metalloproteinase expression is altered in the small and large intestine following fractionated radiation in vivo.

Romany L Stansborough1, Noor Al-Dasooqi2,3, Emma H Bateman2, Joanne M Bowen2, Dorothy M K Keefe2, Richard M Logan4, Ann S J Yeoh2, Eric E K Yeoh2, Andrea M Stringer3, Rachel J Gibson2,3.   

Abstract

PURPOSE: Radiotherapy-induced gut toxicity (RIGT) is associated with significant diarrhoea, pain and rectal bleeding. Matrix metalloproteinases (MMPs) have been reported to be involved in chemotherapy-induced gut toxicity and RIGT following single-dose irradiation in vivo. We therefore proposed MMPs would be involved in the pathobiology of RIGT following fractionated irradiation.
METHODS: Dark Agouti rats were treated with fractionated radiation (3 × 2.5 Gy/week for 6 weeks). Rats were killed at 3, 6 and 15 weeks to represent acute and chronic toxicities. Sections of jejunum and colon were immunostained for MMP-1, MMP-2, MMP-9 and MMP-14. Relative mRNA expression in jejunum and colon was quantified by RT-PCR for MMP-1, MMP-2, MMP-9 and MMP-14. Western blotting was also conducted on jejunum and colon tissue collected at week 6 to determine protein levels of pro- and active MMP-2.
RESULTS: MMP-2 total protein levels, determined by western blotting, significantly increased in both the jejunum (p = 0.0359) and the colon (p = 0.0134) 6 weeks into the fractionated radiation schedule. MMP-1, MMP-2, and MMP-14 mRNA expression significantly increased in the jejunum. MMP-2 mRNA expression was also significantly increased in the colon. Immunostaining of MMP-2 was observed to be increased in both crypt enterocytes and the lamina propria.
CONCLUSIONS: MMP-2 plays a role in the pathobiology of gastrointestinal toxicities following fractionated irradiation. Whilst MMP-1 and MMP-14 mRNA expression was increased, this occurred only in the jejunum, suggesting MMPs are differentially involved in RIGT depending on the intestinal region. Further studies are needed to elucidate the role these mediators play in the development and potentiation of RIGT.

Entities:  

Keywords:  Endothelium; Gastrointestinal; Matrix metalloproteinase; Mucositis; Radiotherapy

Mesh:

Substances:

Year:  2018        PMID: 29754212     DOI: 10.1007/s00520-018-4255-5

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  33 in total

Review 1.  Matrix metalloproteinases as modulators of inflammation.

Authors:  Anne M Manicone; John K McGuire
Journal:  Semin Cell Dev Biol       Date:  2007-07-10       Impact factor: 7.727

Review 2.  Global signatures of protein and mRNA expression levels.

Authors:  Raquel de Sousa Abreu; Luiz O Penalva; Edward M Marcotte; Christine Vogel
Journal:  Mol Biosyst       Date:  2009-10-01

Review 3.  Regulation of matrix metalloproteinase gene expression.

Authors:  Chunhong Yan; Douglas D Boyd
Journal:  J Cell Physiol       Date:  2007-04       Impact factor: 6.384

4.  Cerebral ischemia induces transcription of inflammatory and extracellular-matrix-related genes in rat cerebral arteries.

Authors:  Petter Vikman; Saema Ansar; Marie Henriksson; Emelie Stenman; Lars Edvinsson
Journal:  Exp Brain Res       Date:  2007-09-08       Impact factor: 1.972

5.  Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis.

Authors:  Zhi Yi Ong; Rachel J Gibson; Joanne M Bowen; Andrea M Stringer; Jocelyn M Darby; Richard M Logan; Ann Sj Yeoh; Dorothy M Keefe
Journal:  Radiat Oncol       Date:  2010-03-16       Impact factor: 3.481

6.  A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis, p53, nuclear factor-kappaB, COX-1, and COX-2.

Authors:  Ann S J Yeoh; Rachel J Gibson; Eric E K Yeoh; Joanne M Bowen; Andrea M Stringer; Kar A Giam; Dorothy M K Keefe
Journal:  Mol Cancer Ther       Date:  2007-08       Impact factor: 6.261

7.  Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing.

Authors:  U Schönbeck; F Mach; P Libby
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

8.  Tight junction defects are seen in the buccal mucosa of patients receiving standard dose chemotherapy for cancer.

Authors:  Hannah R Wardill; Richard M Logan; Joanne M Bowen; Ysabella Z A Van Sebille; Rachel J Gibson
Journal:  Support Care Cancer       Date:  2015-10-06       Impact factor: 3.603

9.  Collagenase-1 (MMP-1), matrilysin-1 (MMP-7), and stromelysin-2 (MMP-10) are expressed by migrating enterocytes during intestinal wound healing.

Authors:  M T Salmela; S L F Pender; M-L Karjalainen-Lindsberg; P Puolakkainen; T T Macdonald; U Saarialho-Kere
Journal:  Scand J Gastroenterol       Date:  2004-11       Impact factor: 2.423

Review 10.  MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.

Authors:  Rajesh V Lalla; Joanne Bowen; Andrei Barasch; Linda Elting; Joel Epstein; Dorothy M Keefe; Deborah B McGuire; Cesar Migliorati; Ourania Nicolatou-Galitis; Douglas E Peterson; Judith E Raber-Durlacher; Stephen T Sonis; Sharon Elad
Journal:  Cancer       Date:  2014-02-25       Impact factor: 6.860

View more
  3 in total

1.  Matrix metalloproteases and TIMPs as prognostic biomarkers in breast cancer patients treated with radiotherapy: A pilot study.

Authors:  María Auxiliadora Olivares-Urbano; Carmen Griñán-Lisón; Mercedes Zurita; Rosario Del Moral; Sandra Ríos-Arrabal; Francisco Artacho-Cordón; Juan Pedro Arrebola; Amanda Rocío González; Josefa León; Juan Antonio Marchal; María Isabel Núñez
Journal:  J Cell Mol Med       Date:  2019-09-30       Impact factor: 5.310

Review 2.  Combined Radiochemotherapy: Metalloproteinases Revisited.

Authors:  Verena Waller; Martin Pruschy
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

Review 3.  Immunomodulation by radiotherapy in tumour control and normal tissue toxicity.

Authors:  Urszula M Cytlak; Douglas P Dyer; Jamie Honeychurch; Kaye J Williams; Mark A Travis; Timothy M Illidge
Journal:  Nat Rev Immunol       Date:  2021-07-01       Impact factor: 53.106

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.